Abstract. Glycosaminoglycans undergo significant structural alterations in cancer, namely in terms of their sulfation pattern and hydrodynamic size. Numerous studies have focused on this issue, and have demonstrated that glycosaminoglycans play a crucial role in cancer growth and invasion. However, the majority of the enzymes involved in glycosaminoglycan alterations have yet to be examined in detail. The present study focused on the expression of chondroitin-synthesizing enzymes in colorectal cancer. Specimens from healthy controls and cancer patients were subjected to RT-PCR analysis after RNA isolation, and to Western blotting after sequential extraction. The results indicated that chondroitin polymerizing factor and glucuronyltransferase gradually increased with cancer stage, and were expressed at much higher levels in adenomas compared to adjacent normal tissue. The opposite profile was obtained for chondroitin synthase I. Chondroitin synthase III was present at low levels in all the samples examined; however, its expression was higher in the samples from the cancer patients than in those from the healthy controls. It can therefore be concluded that, among the various factors regulating the structure of glycosaminoglycans in cancer, the differential expression of chondroitin-synthesizing enzymes is of the most significance.
Introduction
Chondroitin sulfate (CS) is a glycosaminoglycan that plays a key role in tissue development and morphogenesis, and also contributes to tumor formation and development (1) . The biosynthesis of CS is accomplished through a variety of enzymes acting in conjunction, named glycosyltransferases and sulfotransferases (2) (3) (4) (5) (6) (7) . The specific glycosyltransferases contributing to the elongation of chondroitin have been characterized: three, CHSY1, CHSY2 and CHSY3, possess dual (glucuronyltransferase and galactosaminyltransferase) enzymatic activities, while the other two, CSGlcA-T and CSGalNAc-T2, act only by transferring glucuronic acid or N-acetylogalactosamine, respectively (8, 9) .
In general, glycosaminoglycans are altered in cancer in qualitative and quantitative terms (10) (11) (12) (13) (14) (15) (16) (17) (18) . In the majority of malignancies, CS levels are increased. In many types of cancer, adjacent macroscopically normal specimens have been observed to possess lower levels of CS compared to tumor specimens. In colon cancer specifically, C-4 sulfated chondroitin/ dermatan was found to be increased by approximately 1.5-fold in normal adjacent and tumor tissue compared to healthy control tissue (11) , while C-6 sulfated chondroitin was increased by 2.5-fold in tumor tissue compared to normal adjacent tissue, and unsulfated chondroitin was detected only in tumor tissue. Differences in CS levels and alterations in its fine chemical structure in pathological states, in particular cancer, have been the subject of numerous studies (12-16). It has been proposed that CS biosynthesis may be affected by changes in the substrate pool, by differential expression of the enzymes involved, or by differences in the secretion pathway of the proteoglycan parent molecule. The exact subcellular localization of the biosynthetic enzymes may also lead to alterations in activity, since the endoplasmic reticulum and Golgi apparatus possess different pH values and ionic strengths (19) . However, as yet no evidence has been presented clearly elucidating these alterations. Therefore, in the present study we examined the expression of the enzymes responsible for CS biosynthesis in colorectal cancer. The expression of the key enzymes was studied at the mRNA level by RT-PCR analysis and at the protein level by Western blotting using specific antibodies. The results indicate that chondroitin-synthesizing enzymes have differential expression in colorectal cancer.
Materials and methods
Chemicals. An RNA extraction kit (Nucleospin RNA II) was obtained from macherey-Nagel (Düren, Germany). The PrimeScript™ one Step RT-PCR kit and a 100-bp DNA ladder were obtained from Takara Bio Inc. (Ōtsu, Japan). Goat antibodies against CHSY1 (N-13), CHPF (CHSY2, e-19) and CHSY3 (C-17) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, uSA). Horseradish peroxidase-conjugated secondary antibodies were from Chemicon (CA, uSA). eCl Western Blotting Substrate was from Pierce (Rockford, Il, uSA). The gene-specific primers were purchased from lieferschein (Germany). All other chemicals used were of the highest available grade.
Tissue origin. macroscopically normal adjacent and tumor tissues were obtained from patients who underwent surgery for colorectal carcinoma at the Surgical Clinic of the General university Hospital of Patras. Two specimens were obtained from each patient, one from the center of the tumor and another of similar weight from areas adjacent to the tumor (macroscopically normal areas), and were stored at -80˚C for further biochemical examination. Clinical information including gender, age, location of the primary tumor and cancer stage was obtained after clinical and pathological diagnosis of the patients (Table I ). The study design was approved by the ethical Committee of the university Hospital of the university of Patras.
Enzyme extraction. Samples from macroscopically normal and tumor tissues were used for the detection of chondroitin synthases and CS glucuronyltransferase. each specimen was finely diced and the macromolecules contained were sequentially extracted for three 24 h periods at 4˚C in the dark in PBS (10 mm disodium phosphate, 0.14 m NaCl, pH 7. then subjected to SDS-PAGe (T, 10%; C, 2.7%) followed by electrotransfer to nitrocellulose (Immobilon NC) membranes and Western blotting detection of the transferred CS synthesizing enzymes as previously described (20) .
RNA extraction and RT-PCR.
Specimens were pulverized in liquid nitrogen and subjected to total RNA extraction using the Nucleospin extraction kit as described by the manufacturer, then treated with RNase-free DNase to remove contaminating genomic DNA. The primers (Table II) were designed using free software (PerlPrimer v1.1.14). The Takara one
Step RT-PCR kit was used to perform the analysis. The RT-PCR conditions were as follows: reverse transcription at 50˚C for 30 min, Taq polymerase activation at 94˚C for 2 min, followed by 35 amplification cycles at 94˚C for 30 sec, 58˚C for 30 sec and 72˚C for 1 min, and a final extension at 72˚C for 10 min. RT-PCR products were separated by gel electrophoresis on 2% w/v agarose gel containing SYBR Gold stain, and the bands were visualized under a uv light. The gels were then scanned and the bands were densitometrically analyzed. Quantitative differences between cDNA samples were normalized to GAPDH.
Isolation and characterization of chondroitin/dermatan sulfate chains. Total chondroitin/dermatan sulfate (CS/DS) was isolated from colon specimens after papain digestion and DeAe-cellulose chromatography, and then quantified after chondroitinase ABC/ACII digestion and separation of the obtained disaccharides using HPlC. Finally, the molecular mass was calculated after gel chromatography on an analytical Sepharose Cl-6B column, as described previously (17, 18) . In this series of experiments, none of the adenomas were used due to the limited quantities obtained from the patients. 
Results
The biochemical characterization of isolated CS/DS chains (Table III) showed increasing levels of glycosaminoglycan in the cancer specimens compared to the samples from healthy tissues, with the increase being more significant at later stages. In addition, the molecular mass of the chains (Table III) showed a stage-related decrease, indicating the presence of increasing levels of core protein substrates of the chondroitinsynthesizing enzymes. These observations are in agreement with previous findings (11, 15, 17, 18) , and suggest a very high biosynthetic rate of CS/DS in cancer, which may be attributable to the increased expression of the related biosynthetic enzymes.
Expression of chondroitin-synthesizing enzymes in healthy tissue.
The mRNA expression of the enzymes examined in the specimens from the healthy controls was very low compared to the reference molecule, GAPDH. CHSY1, CHPF and CSGlcA-T were expressed at about the same level, whereas CHSY3 expression was insignificant (Fig. 1) . In tumors, a marked increase in expression was observed. In the case of CHPF and CSGlcA-T, this increase was substantially higher in benign compared to malignant tumors ( Fig. 1B and D) .
Expression of CHSY1. CHSY1 expression was increased by ~7-fold in the adjacent normal tissue of the benign tumors compared to the tumor and healthy control tissues, as indicated by RT-PCR analysis. In the tumor specimens, CHSY1 expression was high during the early stages. In samples from stage III compared to stage II patients, CHSY1 expression was decreased by ~3-fold in the macroscopically normal specimens and by ~7-fold in the tumor specimens, but remained double that observed in the benign tumors (Fig. 1A) . The results of Western blotting were similar. In benign tumors, the enzyme was expressed 3-fold less than in adjacent normal and healthy tissues, and once again a decrease in the levels of the enzyme was observed at stage III ( Fig. 2A) . The enzyme was identified as two bands of 64 and 66 kDa, mainly in the second and third of the sequential extracts.
Expression of CHPF. CHPF expression was ~2.5-fold higher in the adjacent normal tissue of the adenomas compared to the samples from healthy controls. The increase was much higher in the tumor areas of the adenomas: ~18-fold compared to the adjacent tissue (P<0.001) and 45-fold compared to the healthy tissue. In cancer, the enzyme was expressed at 1.5-fold increased levels in the tumor compared to adjacent normal tissues, and at ~20-fold increased levels compared to the specimens from the healthy controls. The results were statistically significant (P<0.05). A slight stage-related increase was observed in the tumor samples (Fig. 1B) . Similar results were obtained from the Western blotting experiments (Fig. 2B) . The enzyme was identified as a band of 50 kDa almost exclusively in the second sequential extract.
Expression of CHSY3. The CHSY3 gene was expressed equally and at very low levels in the macroscopically normal and tumor specimens, as indicated by RT-PCR analysis and Western blotting (Fig. 1C and Fig. 2C ). However, CHSY3 expression was substantially increased by 3.5-fold compared to the healthy tissue samples, as detected by Western blotting (Fig. 2C) . The enzyme was identified as a 55 kDa band, mainly in the second and third sequential extracts. 
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Expression of CSGlcA-T. The expression of CSGlcA-T was similar to that of CHPF. In benign tumors, CSGlcA-T was markedly elevated by ~40-fold compared to the adjacent normal and healthy tissues (P<0.001), while in the cancer specimens it was decreased (Fig. 1D) . However, at stages I and II, CSGlcA-T expression was apparently identical in the macroscopically normal and malignant tumor specimens, and almost the same as the levels observed in healthy tissue. Furthermore, a significant increase in CSGlcA-T expression of ~6-fold was observed at stage III (P<0.05) compared to stages I and II (Fig. 1D) . However, this increase remained <40% of the levels observed in benign tumors.
Discussion
The aim of the present study was the analysis of the expression of the chondroitin glycosyltransferases in colorectal cancer, and the examination of a possible relationship between their expression and cancer stage. Any alterations in chondroitin chain length or levels may be attributed to the expression of the various chondroitin synthases, to excess substrate (uDP-glucuronate/uDP-galactosamine) and/or to altered enzymatic activities. It is well established that chondroitin synthesis is a process achieved by the concomitant action of the enzymes involved (21) . In vitro experiments have indicated that polymeric unsulfated chondroitin is a better substrate than sulfated chondroitin, and that small chondroitin chains of 10-11 sugar moieties are also good substrates (6) . A complete study of glycosyltransferases, sulfotransferases and dermatan sulfate epimerase in conjunction with chondroitin structure in any type of cancer is warranted. Additionally, these enzymes may be potential therapeutic targets or serve as tumor markers.
The results of the present study indicate that all the chondroitin synthases were elevated in the cancer compared to the healthy tissues. The increase in their expression led to the significant increase in CS/DS levels observed in the cancer tissues. CS/DS levels were additionally more elevated in the tumor tissue than in the adjacent macroscopically normal tissue (11) . The main enzyme which accomplishes this feature is presumably CHPF, a highly expressed enzyme that showed a statistically significant increase in the tumor specimens.
CHSY1 was found to be an enzyme that had a relatively constant expression between macroscopically normal and tumor specimens, but showed a stage-related variation. It is known that CHSY1 uses non-sulfated chondroitin and, to a lesser extent, the sulfated forms of this glycosaminoglycan as substrates (7), whereas CHPF preferentially uses non-sulfated chondroitin and never CSB as substrate (6) . During the late stages of cancer, a relative decrease in the C4S/C6S ratio is observed (11) , which may be attributable to the observed decrease in CHSY1 expression. In addition, the differential expression of CHSY1 and CHPF was observed, most significantly in adenomas.
CHSY3 was generally expressed at insignificant levels, but was higher in tumor compared to healthy tissues. It was reported that CHSY3 expression was very low in most human tissues, while simultaneously its specific activity was low (7) . CHSY3 may therefore contribute to CS synthesis differently than CHSY1.
of note was the similarity in the stage-related expression of CHPF and CSGlcA-T. These two enzymes possess high homology in their amino acid sequence (57%) and similar genomic structure (6). The expression of both CHPF and CSGlcA-T was highest in the tumor areas of adenomatous colon. By contrast, the respective macroscopically normal specimens possessed very low levels of the specific enzymes, similar to the healthy tissues. unfortunately, and due to the limited available quantities of benign tumor specimens, no biochemical characterization of CS/DS chains was performed in these samples; thus, the observations regarding expression were not verified in biochemical terms. It is, however, possible to conclude that both enzymes may play a dinstict role in the formation of benign tumors leading to CS/DS with specific characteristics (fine chemical structure and chain length). The study of these particular features of CS/DS in adenomas is of interest, namely C-6/C-4 sulfation, smaller chondroitin chains or/and unsulfated chondroitin, as they may contribute to carcinogenesis by mechanisms that are to date not fully understood, resulting in proteoglycan formation with specific properties.
Additionally, the regulatory mechanisms of the expression of chondroitin-synthesizing enzymes under normal and pathological conditions are of great interest, as it is possible that growth factors such as TGF-β, PDGF, eGF and FGF affect their expression. A notable finding is that the expression of 4-sulfotransferase isoforms is affected in fibroblasts after treatment by such growth factors (22) . However, it remains unclear whether these growth factors affect the expression of chondroitin polymerizing enzymes.
